Lipid deposition in various sites of the skeletal muscles and liver exhibits a positive correlation with visceral fat accumulation in middle-aged Japanese men with metabolic syndrome

Internal Medicine

Volumn 52, Issue 14, 2013, Pages 1561-1571

  Taira, Shin Ichiro ^a   Shimabukuro, Michio ^b   Higa, Moritake ^c   Yabiku, Kouichi ^a   Kozuka, Chisayo ^a   Ueda, Rei ^a   Sunagawa, Sumito ^a   Ohshiro, Yuzuru ^a   Doi, Mototsugu ^a   Nanba, Toyotaka ^a   Kawamoto, Eriko ^a   Nakayama, Yoshiro ^a   Nakamura, Hideaki ^a   Iha, Takako ^a   Nakachi, Sawako ^a   Tomoyose, Takeaki ^a   Ikema, Tomomi ^a   Yamakawa, Ken ^a   Masuzaki, Hiroaki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Tomishiro Central Hospital   (Japan)

Author keywords

Computed tomography; Diabetes; Ectopic lipid deposition; Metabolic syndrome; Visceral fat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; MIGLITOL; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BACK MUSCLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; HUMAN; ILIOPSOAS MUSCLE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; LIVER; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RECTUS ABDOMINIS MUSCLE; SKELETAL MUSCLE; WAIST CIRCUMFERENCE;

ADULT; AGED; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MUSCLE, SKELETAL; RISK REDUCTION BEHAVIOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880180410     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.0521     Document Type: Article

References (26)

1. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001.
2. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest 112: 83-90, 2003.
3. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444: 881-887, 2006.
4. Mandavilli A, Cyranoski D. Asia's big problem. Nature Med 10: 325-327, 2004.
5. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 883-888, 2000.
6. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273: 3547-3550, 1998.
7. Wang MY, Grayburn P, Chen S, Ravazzola M, Orci L, Unger RH. Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci USA 105: 6139-6144, 2008.
8. Peterson KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300: 1140-1142, 2003.
9. Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90: 3191-3196, 2005.
10. Shimabukuro M, Higa M, Yamakawa K, Masuzaki H, Sata M. Miglitol, a-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: A randomized comparable study. Int J Cardiol 2012 (in press).
11. Matsuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Atheroscler Thromb 12: 301, 2005.
12. Arai H, Yamamoto A, Matsuzawa Y, et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 13: 202-208, 2006.
13. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062, 2005.
14. Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication. Circ J 73: 27-34, 2009.
15. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 1: 2-20, 2010.
16. Hadar H, Gadoth N, Heifetz M. Fatty replacement of lower paraspinal muscles: normal and neuromuscular disorders. Am J Roentgenol 141: 895-898, 1983.
17. Kelley DE, Slasky BS, Janosky J. Skeletal muscle density: effects of obesity and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 54: 509-515, 1991.
18. Hawley RJ Jr, Schellinger D, O'Doherty DS. Computed to-mographic patterns of muscles in neuromuscular diseases. Arch Neurol 41: 383-387, 1984.
19. Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 71: 885-892, 2000.
20. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty Liver: imaging patterns and pitfalls. Radiographics 26: 1637-1653, 2006.
21. Speliotes EK, Massaro JM, Hoffmann U, et al. Liver fat is repro-ducibly measured using computed tomography in the Framingham Heart Study. J Gastroenterol Hepatol 23: 894-899, 2008.
22. Hwang JH, Stein DT, Barzilai N, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 293: E1663-E1669, 2007.
23. Larson-Meyer DE, Newcomer BR, Ravussin E, et al. Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. Diabetologia 54: 869-875, 2011.
24. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89: 104-110, 2000.
25. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307, 2006.
26. Zhong L, Chen JJ, Chen J, et al. Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. J Dig Dis 10: 315-320, 2009.